Rick Orr Net Worth

Rick Orr biography

Rick Orr J.D. serves as Chief Executive Officer, Principal Financial Officer, Director of the Company.D. serves as Chief Executive Officer, Principal Financial Officer, Director of the Company. Rick Orr joined Adynxx in December 2010 as President and Chief Executive Officer, and has more than 15 years of operational, development and legal experience. Most recently, he served as Chief Operating Officer of Corthera where he led the successful sale of the company to Novartis in February 2010. Rick previously served as Sr. Vice President, Operations of Cerexa, a wholly-owned subsidiary of Forest Laboratories. During his tenure at Cerexa, the company completed the successful clinical development of Teflaro® (ceftaroline fosamil), a parenteral antibiotic for the treatment of life-threatening infections. Rick was one of the founders of Cerexa and served as General Counsel until the company was acquired by Forest Laboratories in January 2007. Earlier in his career, he served as the Associate General Counsel of Peninsula Pharmaceuticals where he played a central role in structuring the acquisition of Peninsula by Johnson & Johnson. Prior to working at Peninsula, Rick was an attorney at Cooley LLP. Rick received a JD magna cum laude from the University of San Francisco School of Law. He received a BA from The Ohio State University and an MA from the University of California, Santa Barbara. Rick is a member of the State Bar of California.

What's Rick Orr's mailing address?

Rick's mailing address filed with the SEC is C/O ADYNXX, INC., 100 PINE ST., STE. 500, SAN FRANCISCO, CA, 94111.

What does Adynxx do?

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Adynxx executives and stock owners

Adynxx executives and other stock owners filed with the SEC include:

• Richard Orr,
  Pres, CEO, Principal Financial Officer & Director
• Dr. Julien Mamet Ph.D.,
  Founder, Chief Scientific Officer & Director
• Eckard Weber,
  Director
• Matthew Ruth,
  Director
• Gregory Flesher,
  Director
• Stan Abel,
  Director
• Donald Manning,
  Chief Medical Officer
• Julien Mamet,
  Chief Scientific Officer, Director
• Rick Orr,
  Chief Executive Officer, Principal Financial Officer, Director
• Dennis Podlesak,
  Chairman of the Board
• Kimberley Hebert,
  Sr. Director of Clinical Operations
• Dina Gonzalez,
  Principal Accounting Officer & Sr. VP of Fin.
• William Martin,
  Exec. VP of Corp. Devel. & Operations